H. Lundbeck A/S of Denmark has reported a record DKK 11.3 billion in revenue for 2008 following the double-digit growth of its three marketed drugs for neurological disorders, Cipralex (escitalopram), Ebixa (memantine) and Azilect (rasagiline). ---Subscribe to MedNous to access this article--- Company News
